THTX - Theratechnologies stock slides as Egrifta review runs beyond FDA target date
2024-01-23 08:17:43 ET
Shares of Canadian biopharma firm Theratechnologies ( NASDAQ: THTX ) plunged 30% premarket on Tuesday after the U.S. health regulator said it will continue reviewing the supplemental license application for the company's F8 formulation of tesamorelin beyond the target date....
Theratechnologies stock slides as Egrifta review runs beyond FDA target date